Evaluating quality of life for patients treated with vectorized internal radiotherapy for neuroendocrine tumors.
Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.
This study is trying to see how vectorized internal radiotherapy affects the quality of life for patients with metastatic neuroendocrine tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 4 sites (Saint-Priest-en-Jarez, Saint-Etienne and 3 other locations) |
| Trial ID | NCT06043193 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the quality of life and tolerance of patients undergoing vectorized internal radiotherapy (RIV) for metastatic neuroendocrine tumors. Participants will complete quality of life questionnaires at specified times during their treatment, utilizing a remote computerized data collection system to facilitate participation. Patients will create an account on a patient interface to streamline data extraction and receive automated reminders for questionnaire completion. The study focuses on gathering patient-reported outcomes to better understand the impact of RIV treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who are starting treatment with vectorized internal radiotherapy for neuroendocrine tumors.
Not a fit: Patients who are incarcerated or under legal protection measures will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the quality of life for patients undergoing RIV treatment, potentially leading to improved patient care and treatment protocols.
How similar studies have performed: While this approach is focused on quality of life assessments, similar studies have shown success in evaluating patient-reported outcomes in cancer treatments.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 years; * Patient starting treatment with RIV validated in the RENATEN RCP; * Patient having received written information about the study; * Collection of the patient's non-objection * Patients for whom treatment with RIV is administered within the framework of a clinical trial, may be included in the AURARIV-TNE study according to the written indications written in the 2 nd protocol of the sponsor of the clinical trial; * Patients undergoing re-treatment with RIV can be included; Exclusion Criteria: * Persons deprived of their liberty by a judicial or administrative decision; * Adults subject to a legal protection measure (guardianship, curatorship);
Where this trial is running
Saint-Priest-en-Jarez, Saint-Etienne and 3 other locations
- CHU de Saint-Etienne, Hôpital Nord — Saint-Priest-en-Jarez, Saint-Etienne, France (Recruiting)
- CH Métropole Savoie — Chambéry, France (Recruiting)
- Centre de Lutte Contre le Cancer Jean Perrin — Clermont-Ferrand, France (Recruiting)
- Hospices Civils de Lyon, Hopital Lyon Sud — Lyon, France (Recruiting)
Study contacts
- Study coordinator: Nicolas JACQUET-FRANCILLON, MD
- Email: nicolas.jacquet-francillon@chu-lyon.fr
- Phone: 4 72 35 69 99
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.